相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma
Noemi Puig et al.
ANNALS OF HEMATOLOGY (2013)
Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells
Brian A. Walker et al.
BLOOD (2013)
Extramedullary disease in plasma cell myeloma: the iceberg phenomenon
B. Wirk et al.
BONE MARROW TRANSPLANTATION (2013)
The Level of Minimal Residual Disease in the Bone Marrow of Patients with Multiple Myeloma before High-Dose Therapy and Autologous Blood Stem Cell Transplantation Is an Independent Predictive Parameter
Mark Korthals et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
Laura Rosinol et al.
BLOOD (2012)
Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma
Noemi Puig et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes
J. J. M. van Dongen et al.
LEUKEMIA (2012)
Long-term prognostic significance of response in multiple myeloma after stem cell transplantation
Joaquin Martinez-Lopez et al.
BLOOD (2011)
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
S. Vincent Rajkumar et al.
BLOOD (2011)
Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma
Bruno Paiva et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma
Mervi Putkonen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents
Asher A. Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma
Marco Ladetto et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
Maria-Victoria Mateos et al.
LANCET ONCOLOGY (2010)
Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008
M. Brueggemann et al.
LEUKEMIA (2010)
The role of complete response in multiple myeloma
Jean-Luc Harousseau et al.
BLOOD (2009)
Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients
Bruno Paiva et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
Antonio Palumbo et al.
BLOOD (2008)
Monitoring of minimal residual disease in multiple myeloma after allo-SCT:: flow cytometry vs PCR-based techniques
M. Lioznov et al.
BONE MARROW TRANSPLANTATION (2008)
Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction:: the prognostic impact of achieving molecular response
Pilar Martinez-Sanchez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Individualizing treatment of patients with myeloma in the era of novel agents
Jesus San-Miguel et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
Juan Jose Lahuerta et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis
Xavier Brochet et al.
NUCLEIC ACIDS RESEARCH (2008)
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
Thierry Facon et al.
LANCET (2007)
Using quantification of the PML-RAR alpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia
Carlos Santamaria et al.
HAEMATOLOGICA (2007)
Complete response in multiple myeloma - Clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation
RA Kyle et al.
CANCER (2006)
Thalidomide and hematopoietic-cell transplantation for multiple myeloma
B Barlogie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma
MHC Bakkus et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma
P Corradini et al.
BLOOD (2003)
Incomplete DJH rearrangements of the IgH gene are frequent in multiple myeloma patients:: immunobiological characteristics and clinical implications
D González et al.
LEUKEMIA (2003)
Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects
VHJ van der Velden et al.
LEUKEMIA (2003)
Incomplete DJH rearrangements as a novel tumor target for minimal residual disease quantitation in multiple myeloma using real-time PCR
D González et al.
LEUKEMIA (2003)
Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936
JJM van Dongen et al.
LEUKEMIA (2003)
Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation
AC Rawstron et al.
BLOOD (2002)
Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR
VHJ van der Velden et al.
LEUKEMIA (2002)
Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome
JF San Miguel et al.
BLOOD (2002)
Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation
R López-Pérez et al.
BONE MARROW TRANSPLANTATION (2001)
The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma
FE Davies et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia
OJHM Verhagen et al.
LEUKEMIA (2000)
分享论文
